FDA
-
-
-
-
-
-
-
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
-
-
-
-
-
-
-
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
-
-
-
-
-
-
-
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
-
-
-
-
-
-
-
Citius Oncology closes $18 million stock offering at $1.09 per share
-
-
-
-
-
-
-
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
-
-
-
-
-
-
-
Citius Oncology signs distribution deal with McKesson for LYMPHIR launch
-
-
-
-
-
-
-
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
-
323,592 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

